The use of second or third line nivolumab in advanced non-small cell lung cancer: a west of Scotland experience

被引：0
|
作者：
Ali, C. [1 ]
Yahya, K. [2 ]
机构：
[1] Beatson West Scotland Canc Ctr, Med Oncol, Glasgow, Lanark, Scotland
[2] NHS Lanarkshire, Oncol, Glasgow, Lanark, Scotland
来源：
LUNG CANCER | 2018年 / 115卷
关键词：
D O I：
10.1016/S0169-5002(18)30101-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
75
引用
收藏
页码：S31 / S31
页数：1
相关论文
共 50 条
  • [1] Use of erlotinib in management of recurrent advanced non-small cell lung cancer. The West Of Scotland experience
    Hameed, H.
    Nasim, M. Y.
    Dunlop, D. J.
    LUNG CANCER, 2011, 71 : S4 - S5
  • [2] Second and third line treatment in non-small cell lung cancer
    Favaretto, Adolfo
    Pasello, Giulia
    Magro, Cristina
    Schettino, Clorinda
    Gridelli, Cesare
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 71 (02) : 117 - 126
  • [3] Second or Third Line Nivolumab Versus First Line Nivolumab in Patients with Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)
    Martinez Moreno, E.
    Irigoyen Medina, A.
    Alvarez Cabellos, R.
    Martinez, K. A.
    Santiago, J.
    Rivilla, M.
    Cardenas, J. D.
    Esteban, C.
    Trujillo, B.
    Rosero, A.
    Fernandez, L.
    Ramos, I.
    Ramos, A.
    Chacon, J. I.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S536 - S537
  • [4] Third-line therapy in advanced non-small cell lung cancer
    Geng, Zhen Ying
    Jiao, Shun Chang
    Liu, Shi Cui
    Li, Ying
    Liu, Zhe Feng
    Zhang, Guo Qing
    Wang, Li Jie
    Qu, Feng
    JOURNAL OF BUON, 2013, 18 (04): : 899 - 907
  • [5] Real world efficacy of nivolumab for non-small cell lung cancer (NSCLC) in the West of Scotland (WoS)
    Ansel, S.
    Rulach, R.
    Clark, B.
    Steele, N.
    Maclaren, V.
    LUNG CANCER, 2018, 115 : S35 - S36
  • [6] Second line pembrolizumab for advanced non-small cell lung cancer: experience at University Hospital Waterford
    Farooq, A. R.
    Athanasiyar, V.
    Bracken-Clarke, D.
    Prior, L.
    Senanayeke, S.
    Horgan, A.
    Calvert, P.
    LUNG CANCER, 2018, 115 : S37 - S38
  • [7] SECOND-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER
    Cullen, M.
    LUNG CANCER, 2009, 64 : S13 - S13
  • [8] Second-line treatment of advanced non-small cell lung cancer
    Gridelli, Cesare
    Ardizzoni, Andrea
    Ciardiello, Fortunato
    Hanna, Nasser
    Heymach, John V.
    Perrone, Francesco
    Rosell, Rafael
    Shepherd, Frances A.
    Thatcher, Nick
    Vansteenkiste, Johan
    De Petris, Luigi
    Di Maio, Massimo
    De Marinis, Filippo
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (04) : 430 - 440
  • [9] Prognostic Significance of HALP Score in Second-Line Nivolumab Treatment of Advanced Non-Small Cell Lung Cancer
    Akgul, Fahri
    Gokmen, Ivo
    Gulbagci, Burcu
    Bayrakci, Ismail
    Divriklioglu, Didem
    Bakir Kahveci, Gizem
    Akkus, Aysun Fatma
    Aydin, Tayyip Ilker
    Hacioglu, Bekir
    Erdogan, Bulent
    Topaloglu, Sernaz
    NAMIK KEMAL MEDICAL JOURNAL, 2025, 13 (01): : 6 - 12
  • [10] An evaluation of toxicity and outcomes in West of Scotland patients receiving second line treatment of non-small cell lung cancer
    Laskey, J.
    MacLean, F.
    LUNG CANCER, 2014, 83 : S5 - S6
12345